Scientific Sessions 2019

Discussion

Randomized Clinical Trial Comparing a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves

GALILEO 4D

Victoria Delgado, MD, PhD – Leiden University Medical Center, The Netherlands

Use of anticoagulation and antiplatelets in aortic bioprostheses

AHA/ACC/STS	Type of prosthesis	ESC/EACTS
Clopidogrel 75 mg/day for the first 6 months after TAVR + life-long aspirin 75-100 mg/day) (IIbC)	**TAVR**	Dual antiplatelet therapy for the first 3–6 months after TAVI, followed by lifelong single antiplatelet therapy (IIaC)
Anticoagulation with VKA for at least 3 months after TAVR in low bleeding risk (IIbC)		Single antiplatelet therapy in the case of high bleeding risk (IIbC)
Asipirin 75-100 mg/day in all patients (IIaB)	**SAVR**	Low-dose aspirin (75 - 100 mg/day) for the first 3 months (IIaC)
Anticoagulation with VKA is reasonable for at least 6 months and for as long as 6 months in low bleeding risk (IIaB)		Oral anticoagulation may be considered for the first 3 months (IIbC)

HALT and RLM in bioprostheses

N = 752 ☞ 101 (13%) THV thrombosis



Chakravarty et al Lancet 2017

- Assessed with MDCT
  - median follow-up of 83 days
- Asymptomatic
- Mean gradient 13.8±10.0 mmHg
- Subclinical THV thrombosis associated with increased risk of TIA and all strokes
- Anticoagulation effective therapy

Evolution of HALT and RLM in TAVR

N = 61 ☞ 11% THV thrombosis



HALT/HAM at first CT	HALT/HAM at second CT			
	HALT− HAM−	HALT+ HAM−	HALT+ HAM+	Total
HALT-HAM-	53	7	4	64
HALT+HAM-	5	3	2	10
HALT+HAM+	2	2	7	11
Total	60	12	13	85



Sondergaard et al Eur Heart J 2017

Open questions

1. Correlation between thrombosis rate based on imaging vs. stroke rate



2. When do we need to refer to CT?

The present results

GALILEO 4D

CT-findings



Echo-findings

	HALT (-) N=151	HALT (+) N=44	RLM ≥ 3 (-) N=181	RLM ≥ 3 (+) N=13
LVEF, %	56 ± 10	54 ± 12	55 ± 11	56 ± 13
Mean AV gradient, mmHg	10 ± 5	11 ± 4	10 ± 5	13 ± 4
AVA, cm^2	1.8 ± 0.5	1.7 ± 0.4	1.8 ± 0.5	1.5 ± 0.4
Central AR, mild	1 (0.7%)	1 (2.3%)	2 (1.1%)	0
Central AR, moderate	0	0	0	0
PVR, mild	13 (8.6%)	4 (9.1%)	17 (9.4%)	0
PVR, ≥ moderate	0	1 (2.3%)	1 (0.6%)	0

Stroke/TIA: too few events